Loading clinical trials...
Loading clinical trials...
Post-vaccination Surveillance for Monitoring the Adverse Events Following Immunisation With QDENGA in a Real-world Setting in Malaysia (PRIME-Q)
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination. Another aim of this study is to collect the number of persons vaccinated with QDENGA who need to stay in the hospital because of severe dengue fever. No vaccination will be given as part of this study. The study will only collect data of persons already vaccinated with QDENGA who agree to participate.
Age
4 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Universiti Malaya
Kuala Lumpur, Kuala Lumpur, Malaysia
Universiti Putra Malaysia
Serdang, Selangor, Malaysia
Start Date
September 26, 2024
Primary Completion Date
May 8, 2027
Completion Date
May 8, 2027
Last Updated
June 12, 2025
2,000
ESTIMATED participants
No Intervention
OTHER
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06741683